Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
- 96 Percent Complete Remission Rate in Newly Diagnosed Hodgkin Lymphoma Patients Treated with ADCETRIS in Combination with AVD Chemotherapy -
- Safety and Response Data Support Ongoing Phase III Trial of ADCETRIS and AVD Chemotherapy in Patients with Newly Diagnosed Hodgkin Lymphoma -
Ricardo says: "This drug is no humbug"
Good luck to all !